Noncyclam tetraamines inhibit CXC chemokine receptor type 4 and target glioma-initiating cells

Laia Ros-Blanco, Judit Anido, Ramon Bosser, José Esté, Bonaventura Clotet, Ana Kosoy, Luis Ruíz-Ávila, Jordi Teixidó, Joan Seoane, José I. Borrell

Research output: Contribution to journalArticleResearchpeer-review

9 Citations (Scopus)


The three stereoisomers of the noncyclam compound 1 (1(R,R), 1(S,S), and the meso form 1(S,R)) and their corresponding tetrahydrochlorides 11 were prepared from (S)- and (R)-2-methylpiperidine. We have evaluated their inhibitory activity on the CXC chemokine receptor type 4 (CXCR4), toxicity properties, and assessment of their effect on glioma initiating cells (GICs) in comparison with the prototype compound AMD3100. The IC50 values determined on human recombinant (CHO) cells showed very similar inhibitory activities albeit a lower KB for AMD3100, with the 1(R,R) isomer being second in potency. All the compounds showed low cardiac toxicity but, contrary to AMD3100, gave maximum nonlethal doses of around 2.0 mg/kg. The CXCR4 inhibitors had an effect on the state of differentiation of GICs, decreasing the percentage of CD44+ cells in glioblastoma multiform neurospheres in vitro. Moreover, these CXCR4 inhibitors blocked the capacity of cells to initiate orthotopic tumors in immunocompromised mice. © 2012 American Chemical Society.
Original languageEnglish
Pages (from-to)7560-7570
JournalJournal of Medicinal Chemistry
Issue number17
Publication statusPublished - 13 Sept 2012


Dive into the research topics of 'Noncyclam tetraamines inhibit CXC chemokine receptor type 4 and target glioma-initiating cells'. Together they form a unique fingerprint.

Cite this